CTIS2022-502139-20-00进行中（未招募）1 期
Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation – a randomized, double-blind, placebo-controlled, investigator-initiated study - PROTECT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma, Age = 18 years, BMI = 18.5, ECOG performance status = 2, Literate in Danish and/or English
排除标准
- •Diabetes, Pregnant or nursing females, Previous or current gastrointestinal malignancy, Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Family is defined as a first degree relative, Genetic disorders with defective tissue repair (e.g. Fanconi anaemia), History of pancreatitis (acute or chronic), Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of < 30 ml/min/1.73 m2 as defined by KDIGO 2012 classification4, Impaired liver function, defined as ALT = 2.5 times upper normal limit at screening, Known or suspected hypersensitivity to semaglutide or other GLP-1RA, Inflammatory bowel disease
研究者
相似试验
尚未招募
2 期
Semaglutide in Auto-HSCTIntestinal MucositisInflammationChemotherapeutic ToxicityNCT06449625Klaus Gottlob Müller40
进行中（未招募）
1 期
Semaglutide in the treatment of type 2 diabetes – effects on prevention of weight regain and metabolism after diet induced weight lossEUCTR2020-002712-51-FIKirsi Pietiläinen75
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageEUCTR2018-004484-31-DEovo Nordisk A/S69
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageNon-alcoholic steatohepatitis Compensated liver cirrhosisMedDRA version: 20.1 Level: PT Classification code 10053219 Term: Non-alcoholic steatohepatitis System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: LLT Classification code 10024667 Term: Liver cirrhosis System Organ Class: 10019805 - Hepatobiliary disordersEUCTR2018-004484-31-ESovo Nordisk A/S69
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageEUCTR2018-004484-31-GBovo Nordisk A/S69